Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card 鈥淎骋础滨狈厂罢鈥� Misguided Proposals 1 and 2
SINOVAC鈥檚 Board of Directors encourages shareholders to follow recommendations of leading independent proxy advisory firms ISS and Glass Lewis and VOTE to KEEP the Current Board in Place
VOTE as soon as possible 鈥� only the latest-dated vote will count
Due to limited venue capacity, shareholders are strongly encouraged to participate in the Special Meeting electronically
To learn more, including how to vote, visit:
Valid shareholders are urged to follow the recommendations of leading independent proxy advisory firms, (鈥淚SS鈥�) and (鈥淕lass Lewis鈥�), to vote the WHITE proxy card 鈥淎骋础滨狈厂罢鈥� proposals 1 and 2. Shareholders should vote AS SOON AS POSSIBLE to RETAIN the Current Board and OPPOSE the Reconstituted Imposter Former Board Slate.
SPECIAL MEETING INFORMATION
The Special Meeting will be held at Stapleton Chambers Inc., Suite No. 2, Stapleton House, Stapleton Lane, Saint John鈥檚,
SINOVAC shareholders may only participate in the online virtual meeting by registering in advance at prior to the deadline of 8:00 p.m. Atlantic Standard Time on July 7, 2025 (8:00 a.m. China Standard Time on July 8, 2025). Please have your voting instruction form, proxy card or other communication containing your control number available and follow the instructions to complete your registration request. Upon completing registration, shareholders will receive further instructions via email, including unique links that will allow them to access the Special Meeting and will permit them to submit questions during the Special Meeting.
ISS AND GLASS LEWIS RECOMMENDATIONS
Leading independent proxy advisory firms ISS and Glass Lewis recommend that SINOVAC shareholders vote to KEEP the current SINOVAC Board in place by voting the WHITE proxy card 鈥�AGAINST鈥� the election of the Reconstituted Imposter Former Board Slate at the upcoming Special Meeting.
Highlights from the ISS and Glass Lewis Reports include1 (emphasis added):
- 鈥淸T]he [current] board appears to be working to pay SVA shareholders their fair share of dividends, and to resume trading of the company's shares, which are the two most pressing issues currently facing SVA shareholders.鈥� (ISS Report, July 3, 2025)
- 鈥淭he former board [鈥 presided over transactions that enabled the payment of billions of dollars in dividends to minority shareholders of SLS, all while it told SVA shareholders that it had no plans to pay dividends to them.鈥� (ISS Report, July 3, 2025)
- 鈥�[T]he current board has demonstrated credible progress in restoring governance stability and operational normalcy. [...] The Dissident Group鈥檚 proposals, by contrast, rest on an inconsistent platform, rely on individuals linked to the governance failures of the past, and raise material questions about their ability to credibly resolve the challenges ahead.鈥� (Glass Lewis Report, July 1, 2025)
- 鈥淸The Dissident Group]鈥檚 shifting criticisms, from claiming dividends are insufficient to later arguing they are excessive, reflect what we view as a reactive approach that appears driven more by tactical positioning in a campaign rather than long-term value creation.鈥� (Glass Lewis Report, July 1, 2025)
YOUR VOTE IS IMPORTANT
Your vote determines SINOVAC鈥檚 future, receipt of your dividend payments and the long-term value of your investment. The facts are clear, and so is the choice.
We urge you to vote on the WHITE proxy card:
- 鈥�AGAINST鈥� Proposal 1 to remove the current SINOVAC Board.
- 鈥�AGAINST鈥� Proposal 2 to appoint the Reconstituted Imposter Former Board Slate.
DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke your vote by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count!
For more details on the misdeeds and shareholder harm caused by the Imposter Former Board and Dissenting Investor Group, visit our website .
____________________ 1 Permission to use quotations was neither sought nor obtained. |
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.
The COVID-19 vaccine, CoronaVac庐, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive庐, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive庐, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1庐, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu庐, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
Important Additional Information and Where to Find It
In connection with SINOVAC鈥檚 Special Meeting, SINOVAC has filed with the
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the
View source version on businesswire.com:
Investor and Media Contact
FGS Global
[email protected]
Source: The Board of Directors of Sinovac Biotech Ltd.
